Objective: Bronchiectasis and especially related mortality has gained growing interest in recent years.The aim of our retrospective study was to determine the factors which may influence and indicate mortality in our bronchiectasis patients throughout 13 years. Material and Methods: Patients with ICD-10 code J47 depicting bronchiectasis between 1.1.2003 to 31.12.2015 were evaluated using database of our hospital.694 out of 1470 patients who had highresolution computed tomography (HRCT) scan confirming the presence of bronchiectatic lesions were included. Results: Female/male ratio was 1.09. Mean age of the patients was 45.9±15.7 years. Sputum culture results were available in 365 (52.6%)of the patients.Pseudomonas aeruginosa was the leading pathogen, which was found in 68 (20.7%) patients.28 (4%) patients have died during the 13 year period, and the overall survival was 125,3 months. In general 5 (4.4%) out of 112 patients who underwent surgery were lost, 3 of them belonging to the transplantation group. 3 out of 9 patients (33%) who underwent lung transplantation were lost within 3 years.There was no statistically
Introduction
Bronchiectasis is a chronic lung disease characterized by a clinical syndrome of cough, sputum production and bronchial infection. It is defined radiologically by permanently dilated bronchi, which lead to impaired mucociliary clearance, chronic airway inflammation and bacterial colonization. The aims of treatment are to prevent exacerbations, reduce symptoms, improve quality of life, and stop disease progression as stated in the European Respiratory Society guidelines for the management of adult bronchiectasis [1] . Bronchiectasis may also lead to life-threatening hemoptysis, respiratory failure and death. Nowadays two scoring systems are in usage which aim to predict severity and mortality of bronchiectasis [2] . They include age, airway obstruction, body mass index, dyspnea, affected lobe number, exacerbations, hospitalization and microbiological status as variables predicting mortality. An exacerbation of bronchiectasis is defined according to British Thoracic Society criteria as "an acute deterioration with worsening local symptoms (cough, increased sputum volume, purulence, or change of viscosity, with or without increasing wheeze, breathlessness, haemoptysis) and/or systemic upset". Several retrospective and prospective studies targeting different factors related to mortality have been published in the last decade [3] [4] [5] . Recent studies which focus specifically on Pseudomonas (P.) aeruginosa and its role in bronchiectasis present valuable data which can direct future efforts on this field. In general, sputum microbiology, radiological severity, age, hospitalizations are the most commonly encountered factors which relate to mortality [6, 7] . Surgical removal of the affected site or lung transplantation are non-medical options in patients with bronchiectasis who have severe suppurative complications, life-threatening hemoptysis and respiratory insufficiency. The recent guidelines from the British Thoracic Society (BTS) specifically note scarce data on the results of surgery and specifically lung transplantation for bronchiectasis [8] . It is still debatable which patients to refer to operation and when to operate. Resections and lung transplantation may save lives in this population. The aim of our study was to determine the role of clinical factors and surgery including lung transplantation in mortality in our bronchiectasis patients throughout 13 years in a single institution.
Materials and Methods
Patients with ICD-10 code J47 depicting bronchiectasis between 1.1.2003 to 31.12.2015 were retrospectively evaluated using electronic database of our hospital. The study included only the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Uzel FI, Altın S, Yentürk E, et al. Managing bronchiectasis: 13 years of experience from sputum to lung transplantation. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.19040 ©Copyright 2019 by Turkish Thoracic Society -Available online at www.turkthoracj.org patients who had thoracic high resolution computed tomography (HRCT) and was diagnosed at our hospital with a minimum follow-up time equal to or more than 12 months. 1470 patients were found to have the diagnosis of bronchiectasis. 776 of them did not have HRCT confirming the diagnosis or had follow-up time less than 12 months, so 694 out of 1470 patients who had HRCT scan confirming bronchiectatic lesions and were followed at least 12 months were included in our study. The status of survival was detected in December 2016 using 'Declaration of Death Online System' of the Ministry of Health, Turkey. The study received approval from Ethical Committee of our hospital with registration number 2016/08. As the study was a retrospective cohort study, no informed consent was obtained from the patients. Images obtained using 1 mm collimation at full inspiration were reviewed and bronchiectasis was meant to be present if there was one or more of the following criteria: a broncho-arterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura. The results of sputum culture were obtained from the database of our hospital. Any sputum culture results at any time -whether normal flora or pathological growth-was included in the study. Clinical data, radiological localization, sputum culture, surgical treatment and mortality were investigated.
Statistical Analysis
Data were expressed as mean with standard deviation (SD) and 95% confidence intervals (CI). The chi-square test and Mann Whitney U test were used for comparison of categorical and numerical data, respectively. For percent survival and presentation of the figures on total mortality and mortality sub-analysis, a Kaplan-Meier analysis was performed with a log-rank test to compare different etiology subgroups. For the univariate mortality analysis, Cox proportional hazard regression analysis was used to estimate hazard ratios (HR) and their 95% confidence intervals of several parameters possibly predicting mortality. For multivariate analysis of factors associated with mortality, a multivariate Cox regression analysis was performed. Variables that were significant in the univariate model were included in the multivariate analysis. Analysis was performed using SPSS 20.0.0. p values were considered to be significant if lower than 0.05 and two-tailed testing was performed.
Results
There were 362 female (52.2%) and 332 (47.8%) male patients. The female/male ratio was 1.09. Mean age of the patients was 45.9±15.7 years. Median duration of follow-up of the patients was 59 ± 32 months. 23.6% of the patients smoked cigarette in some time during their life. More than half of the patients were never smokers (59.2%). Sputum culture results were available in 337 (48.5%) of the patients. Details about microbiological spectrum including culture positivity in more than 1% of the patients are given in Table 1 . P. aeruginosa with accompanying 2 different bacteria was detected in 12 patients. P. aeruginosa with accompanying 3 different bacteria was detected in 6 patients. Mixed double isolation was detected in 19 patients and mixed triple isolation was found in 9 patients. Spirometric results were available in 251 (36%) of the patients. The spirometry results were within normal limits in 17.6% of the patients (n=92). The majority of patients had a combined ventilatory This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Uzel FI, Altın S, Yentürk E, et al. defect with a proportion of 38.4% (n=201). Obstructive ventilatory defect was found in 21.2% (n=111) and restrictive defect was found in 22.9% (n=120) of the study population. FEV1 level was %65 with a standard deviation of ± 24.8. In 58.2% (n=405) of the patients the disease was unilaterally located. In 41.8 % (n=292) of the patients both lungs were involved. In 40.1 % of the patients the disease was confined to only one lobe. Two lobes were affected in 29.7% of the patients. In 3.7% of them all the lobes in both lungs were severed. Left lower lobe was the predominant location of bronchiectasis (62.2%). Right lower lobe followed it with a percentage of 40.6%. Right upper lobe was affected in 31.6% of the patients. Left upper lobe followed with a percentage of 28.4%. Right middle lobe (28.2%) and lingula (22.5%) were the least commonly diseased lobes. Table 2 summarizes the operations performed during 13 years period. 69 (61.6%) of the operations were left-sided. Left lower lobectomy made up 36.6 % (n=41) of all the procedures and was the leading operation. Right lower lobectomy was in the second position with 10.7% (n=12). 9 patients had bilateral lung transplantation because of the involvement of both lungs leading to respiratory insufficiency. Lung transplantation started to be performed in our institution in the year of 2013. 5 patients were operated in 2013 and 2 patients got operated in 2014. The remaining 2 patients received bilateral transplantation in 2015 and in 2016, respectively.
In general 5 (4.4%) out of 112 patients who underwent surgery were lost, 3 of them belonging to the transplantation group. 3 out of 9 patients (33%) who underwent lung transplantation were lost within 3 years. The causes of death were as follows: One of them died (56 years old male patient) because of respiratory insufficiency after later than one month following surgery. One patient (35 years old female patient) received a retransplantation after 2 years of the first procedure because of chronic rejection and died of septic complications after more than one month following the second surgery. The last patient (48 years old female patient) died after 2 years post-transplantation because of respiratory insufficiency. Sputum cultures of the two female patients were positive for P.aeruginosa and the male patient had E.coli growth in sputum culture. Table 3 summarizes the microbiological spectrum of patients who were operated. The first patient (58 years old male) from the non-transplant group died after emergent massive hemoptysis-related left sided thoracotomy. The second patient (61 years old male) was lost ten years after left sided thoracotomy because of ischemic heart disease. Sputum cultures were positive for K.pneumoniae and P. aeruginosa, respectively. The diseaserelated mortality rate in the non-transplant group was 1/103, namely 0.97%. 28 (4%) patients have died during the 13 year period, and the overall survival was 125.3 months (95%CI; 123.1 to 127.5). The case fatality rate in 12 months was 3/694 (0.43 %); 9/694 in 36 months (1.3%); in 60 months 16/694 (2.3%) and in 120 months %4. There was no statistically significant difference in survival between patients who underwent surgery or not (p>0.05). The cause of death in 14 of the patients was recorded as respiratory insufficiency in different hospitals. We were not able to find out the real causes of death in 9 patients. In univariate Cox regression mortality analysis age, FEV1, P. aeruginosa, E.coli, hospitalization and ICU admission had a p value less than 0.01. There were significant mortality rates in ≥30 years group, however there has been no fatalities in patients that are younger than 30 years of age (p<0.005). The involvement of 3 or more lobes of the lung was found in 209 (30%) patients, and there was a relationship with poor survival in patients older than 30 years (p=0.032). The overall survival in patients with less than 3 lobes involvement was 127.5 months (95%CI; 125.6 to 129.4), and in patients 3 or more lobes involvement was 122.5 months (95%CI; 118.5 to 126.4). 440 patients were only treated as outpatients during follow-up. 138 have been This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Uzel FI, Altın .005) . On the other hand, the presence of P. aeruginosa was not associated with surgical treatment of the bronchiectasis (p=0.9). Apart from this, the presence of E. coli in sputum was also associated with poor survival in our patients (p<0.01). When all these factors were evaluated in the multivariate analysis, only P.aeruginosa reached statistical significance in predicting mortality.
Discussion
Our results show that during 13 years, 4% of our patients died. Univariate analysis showed higher mortality according to age, FEV1, radiological extent/severity, P. aeruginosa, E.coli, hospitalization and ICU admission. Multivariate analysis resulted in the major risk factor for higher mortality as the existence of P.aeruginosa. Our mortality rate is relatively lower when compared to other similar studies. Loebinger et al. reported 8.8-year mortality as 16.5 % [4] and in the study of Goeminne et al [3] the mortality was 20.4% in a median follow-up of 5.18 years. Önen et al [5] detected 16.3% mortality during 4-year follow-up of the patients. Our study population was comparable with the recent literature in terms of age and gender distribution [1, [3] [4] [5] . More than half of the patients were never smokers (59.2%) which were higher than in the study of Goeminne et al. [3] , but lower than in the population of Önen et al [5] , which was 75.5%. We have to mention that we have missing data due to heterogeneity of our file system. The involvement of 3 or more lobes of the lung was found in 209 (30%) patients. This is lower than the population of the study of Goeminne et al [3] , which may partly explain the higher mortality rate in their study. Lateralization of disease showed predominance in favor of left lower lobe, but this had no association with mortality. Hospitalization rates may be misleading when comparing patient outcomes, as the specifications of the institution -reference center/training hospital or general hospital-bed availability, and indications for inpatient treatment may differ. More than half of our study population was treated as outpatients. The higher rate of mortality in hospitalized patients is expected as more severe patients with exacerbations, lower respiratory capacity, colonization with strong pathogens and hemoptysis constitute this group. Multiple hospitalizations had a significant negative impact on survival in our population and this was in accordance with scoring systems predicting mortality [2] . Intensive care unit admission was also associated with mortality. The indications for ICU admission rely on generally defined objective criteria. The association of this fact with higher mortality is therefore beyond dispute. Of the patients who had spirometric evaluation (75.5%), the majority had either combined or obstructive ventilatory defect with a mean FEV1: 65%± 24.8. Although being a factor related to mortality in univariate analysis, FEV1 lost this significance in multivariate analysis. It still has its place in FACED score and bronchiectasis severity index with age and hospitalization, where they proved to be even strong in predicting mortality over a longer period than originally described [3] . Pseudomonas aeruginosa is an opportunistic pathogen. It is well known that in cystic fibrosis (CF) bronchiectasis, P. aeruginosa colonization leads to rapid decline in lung function and premature mortality. This bacterium rapidly adapts to chronic infection in lung and develops resistance. Finch et al.
[6] made a systematic review to find out whether colonization with P. aeruginosa influences prognosis and/or is associated with This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Uzel FI, Altın S, Yentürk E, et al. Managing bronchiectasis: 13 years of experience from sputum to lung transplantation. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.19040 ©Copyright 2019 by Turkish Thoracic Society -Available online at www.turkthoracj.org cross-sectional features of severity. They included studies with a total of 3683 patients. P. aeruginosa was significantly linked to mortality, hospital admissions and exacerbations of bronchiectasis. The risk of death was found to be threefold. So this pathogen proved to be both a marker of severe disease and associated with a worse prognosis. In our retrospective study, we were unable to determine colonization, the most frequent definition of which is two positive cultures at least 3 months apart over the course of 12 months. The presence of P.aeruginosa in any time in sputum culture was related significantly to mortality and was associated with poor prognosis with survival of 109.3 months (95%CI; 99.8 to 118.8) (p<0.005). This finding is in accordance with the analysis of Finch et al. [6] , supporting their conclusion that patients with P.aeruginosa deserve specific treatment to reduce the risk of mortality. Wang et al. [7] recently published a retrospective study to evaluate the clinical characteristics and prognostic value of P. aeruginosa in adult patients with bronchiectasis. P. aeruginosa was the most commonly isolated pathogen (43.3%) in 1188 patients with sputum or bronchoalveolar lavage fluid (BALF) data. This was relatively higher than our study population where we had P. aeruginosa growth in 20% of the patients with sputum culture. This study and ours had some features in common like being a single and specialized center and taking allcause mortality as an endpoint. They found that the isolation of P. aeruginosa was related to worse clinical and radiological condition, worse lung functions, more exacerbations and higher mortality. Depending on similar results, Pasteur MC et al. [9] proposed in British Thoracic Society guideline for non-CF bronchiectasis that P.aeruginosa colonization status should play a key role in the assessment of disease severity. In our study, 4 (3.6%) out of 110 patients who underwent surgery were lost. This was not immediate postoperative mortality, but again 'all-cause mortality' due to retrospective design. Fan, L.C. et al.designed a meta-analysis to evaluate the efficiency and safety of surgery in the management on non-cystic fibrosis bronchiectasis [8] . The overall pooled mortality was calculated as 1.5% of a total of 38 studies from 1969 to 2014. The lower mortality can be explained by the fact that both children and adults were included and elective rather than emergency surgeries predominated. Three out of 9 patients (33%) who underwent lung transplantation were lost within 3 years. Sputum cultures of the two female patients were positive for P.aeruginosa and the male patient had E.coli growth in sputum culture. Data on transplantation in bronchiectasis are limited. Rademacher J et al [10] published a retrospective analysis of 34 patients who underwent lung transplantation with a primary diagnosis of bronchiectasis. The most common organism of pre-and posttransplant chronic airway infection was P. aeruginosa. 15 of the 34 patients (44%) were lost within the study period, but early deaths -those within one year-were attributed to immunodeficiency. Overall survival of patients with bronchiectasis after transplantation was comparable to other diseases. So we suggest that with growing experience, lung transplantation will gain evidence in treating patients with severe bronchiectasis. There are weak parts of our study: as it based on retrospective data, we could not find out some parameters like the load of active smoking, associated comorbidities, exacerbation rates, the details of microbiological studies -infection in exacerbation or colonization-, the details of the treatment -eradication therapy, long-term antibiotic therapy, changes in the treatment according to culture results, the availability of pulmonary rehabilitation including airway clearance techniques -, the investigations concerning the etiology of bronchiectasis -CF, immune deficiencies, etc.-and the real reason of death in some patients. Malnutrition data including body mass index, which is an important determinant of mortality is also one of our missing points. As our hospital is a reference center for pulmonary diseases in our country, probably more severe patients are treated and our patients may not reflect the real spectrum of bronchiectasis in patients in general. That may This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Uzel FI, Altın have caused some selection bias. In addition, we used 'all-cause mortality' instead of 'bronchiectasisrelated mortality' and this might lead to exaggerated influence of P.aeruginosa infection on mortality. We were not able to define the groups which were colonized or infected with P. aeruginosa. Apart from this, there is a lack in data both worldwide and concerning this study describing the effect of organisms other than P. aeruginosa on prognosis. Only presence of E.coli in sputum culture showed association with mortality in univariate analysis but lost its power in multivariate analysis thereafter. Other organisms may influence the outcome of these patients to a lesser extent than P. aeruginosa, which also found its place in the Bronchiectasis Severity Index [11] .
Our study may fill a gap in the literature by contributing a large population of bronchiectasis patients from Turkey. As our hospital is a reference center for pulmonary diseases and thoracic surgery, this pooled experience can be further improved by prospectively following the patients of this cohort. 694 patients are more than the populations on which Bronchiectasis Severity Index and FACED score depended on [2] . In the light of accumulating data and the results of our study, all bronchiectasis patients should have sputum microbiological results in order to detect P.aeruginosa as soon as possible. As P. aeruginosa accompanies severe disease and mortality depends on multiple factors, the way to conclusively prove the isolated effects of it on outcome can be achieved through a large randomized controlled trial of eradication treatment, which is recommended clearly in the last consensus statement by EMBARC [12] . We do not know why some patients become colonized with P.aeruginosa. This fact is also highlighted by Aliberti et al. [12] and shows why we need more studies investigating the genetic, microbiological, inflammatory and clinical susceptibility factor for the colonization. In summary, we may draw the conclusion that isolation of P.aeruginosa in a patient with bronchiectasis should be taken seriously. It can be suggested that eradication treatment according to guidelines will help reduce mortality of bronchiectasis worldwide. Surgery is still an option of treatment in severe bronchiectasis and lung transplantation may be a life-saving way of managing end-stage disease.
